Our top pick for
Finder may earn compensation from partners, but editorial opinions are our own. Advertiser Disclosure
Omeros Corporation is a biotechnology business based in the US. Omeros Corporation shares (OMER) are listed on the NASDAQ and all prices are listed in US Dollars. Omeros Corporation employs 277 staff and has a trailing 12-month revenue of around 0.00.
|Latest market close||$6.32|
|52-week range||$5.45 - $23.14|
|50-day moving average||$11.43|
|200-day moving average||$14.81|
|Wall St. target price||$35.00|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-2.28|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-10-20)||-1.25%|
|1 month (2021-09-27)||-56.50%|
|3 months (2021-07-27)||-55.80%|
|6 months (2021-04-27)||-64.99%|
|1 year (2020-10-26)||-38.16%|
|2 years (2019-10-25)||-60.33%|
|3 years (2018-10-26)||16.16|
|5 years (2016-10-26)||8.16|
|Revenue TTM||$86.6 million|
|Gross profit TTM||$6.2 million|
|Return on assets TTM||-65.87%|
|Return on equity TTM||0%|
|Market capitalisation||$405.6 million|
TTM: trailing 12 months
There are currently 9.9 million Omeros Corporation shares held short by investors – that's known as Omeros Corporation's "short interest". This figure is 4.9% down from 10.4 million last month.
There are a few different ways that this level of interest in shorting Omeros Corporation shares can be evaluated.
Omeros Corporation's "short interest ratio" (SIR) is the quantity of Omeros Corporation shares currently shorted divided by the average quantity of Omeros Corporation shares traded daily (recently around 470809.38989514). Omeros Corporation's SIR currently stands at 20.98. In other words for every 100,000 Omeros Corporation shares traded daily on the market, roughly 20980 shares are currently held short.
However Omeros Corporation's short interest can also be evaluated against the total number of Omeros Corporation shares, or, against the total number of tradable Omeros Corporation shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Omeros Corporation's short interest could be expressed as 0.16% of the outstanding shares (for every 100,000 Omeros Corporation shares in existence, roughly 160 shares are currently held short) or 0.1649% of the tradable shares (for every 100,000 tradable Omeros Corporation shares, roughly 165 shares are currently held short).
A SIR above 20% would generally be considered very high, pointing to a pessimistic outlook for the share price, with a discouraging number of investors currently willing to bet against Omeros Corporation.
Find out more about how you can short Omeros Corporation stock.
We're not expecting Omeros Corporation to pay a dividend over the next 12 months.
Omeros Corporation's shares were split on 1 October 2009.
Over the last 12 months, Omeros Corporation's shares have ranged in value from as little as $5.45 up to $23.14. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Omeros Corporation's is 1.1693. This would suggest that Omeros Corporation's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).
Omeros Corporation, a commercial-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting inflammation, complement-mediated diseases, disorders of the central nervous system (CNS), and immune-related diseases. It provides OMIDRIA for use in cataract surgery or intraocular lens replacement in the United States. The company's clinical programs include Narsoplimab (OMS721/MASP-2) for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (HSCT-TMA); that is in Phase III clinical trial for immunoglobulin A nephropathy (IgAN), atypical hemolytic uremic syndrome (aHUS), and COVID-19; and Phase II clinical trial to treat lupus nephritis and other renal diseases. Its clinical programs also consist of PPAR? (OMS405) to treat opioid and nicotine addiction; PDE7 (OMS527) for treating addiction and compulsive disorders, and movement disorders; and MASP-3 (OMS906) for paroxysmal nocturnal hemoglobinuria (PNH) and other alternative pathway disorders. The company's preclinical programs comprise MASP-2-small-molecule inhibitors used for the treatment of aHUS, IgAN, HSCT-TMA, and age-related macular degeneration; longer-acting second generation antibody targeting MASP-2; and MASP-3-small-molecule inhibitors to treat PNH and other alternative pathway disorders. Its preclinical programs include G protein-coupled receptor (GPCR) platform, including GPR174, GPR151, GPR161, and other Class A orphan GPCRs for treating immunologic, immuno-oncologic, metabolic, CNS, cardiovascular, musculoskeletal, and other disorders. The company was incorporated in 1994 and is headquartered in Seattle, Washington.
Steps to owning and managing ProShares Bitcoin Strategy ETF units.
Everything we know about the The Real Good Food Company IPO, plus information on how to buy in.
Everything we know about the Lulu’s Fashion Lounge Holdings IPO, plus information on how to buy in.
Everything we know about the Allarity Therapeutics IPO, plus information on how to buy in.
Everything we know about the Jupiter Neurosciences IPO, plus information on how to buy in.
Everything we know about the Mainz Biomed IPO, plus information on how to buy in.
Everything we know about the Progressive Care IPO, plus information on how to buy in.
Everything we know about the Desert Peak Minerals IPO, plus information on how to buy in.
Everything we know about the Vaxxinity IPO, plus information on how to buy in.
Everything we know about the Entrada Therapeutics IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.